Letters sent to healthcare professionals in July 2015

Last month, letters were sent regarding SGLT2 inhibitors and Xgeva鈻� (denosumab).

From:
Medicines and Healthcare products Regulatory Agency
Published
19 August 2015

Last month, letters were sent regarding:

  • .: risk of diabetic ketoacidosis (see also June Drug Safety Update)

  • Xgeva鈻� (): contraindication in patients with unhealed lesions from dental or oral surgery; introduction of patient reminder card for risk of osteonecrosis of the jaw (see also July Drug Safety Update

Article citation: Drug Safety Update volume 9 issue 1 August 2015: 2

Updates to this page

Published 19 August 2015